s / Osteoarthritis and Cartilage 22 (2014) S57–S489 S477 C8, C12, C15, C16, C18 linear alkyl amines and a benzyl amine, were tested for the inhibitory activity against ChC. The inhibitor potency showed to be directly correlated to the length of the alkyl chain. The C16 alkyl amide derivative HYADD 4 was identified as lead compound (Ki1⁄4 6.2 1.6 mM), on the basis of the best compromise between potency and solubility. With the aim of assessing the specificity of the effect, HYADD 4 was then screened vs 10 different human MMP catalytic subunits, showing higher selectivity for MMP8 and MMP13. The Ki against human MMP13 was found to be in the micromolar range (61.7 7.0 mM). Finally, since MMP13, unlike MMP8, is involved in OA progression, an ex vivo study was performed by incubating HYADD 4 in SF from patients with inflammatory arthritis: the Ki value obtained (106.1 9.2 mM) was comparable to that observed in vitro, thus validating the inhibitory activity against MMP13. Conclusions: These data suggest that the extremely hydrophobic side chain of HYADD 4, whose water solubility is boosted by the HA backbone, is pivotal in the mechanism of MMP competitive inhibition. The polymer structure suggests that the alkyl side chain could easily and selectively dock the hydrophobic S1’ pocket in the MMP catalytic domain. The hexadecyl derivative shows the best performance against MMP13 and MMP8, as confirmed also in an ex-vivo experiment in SF vs human MMP13. Furthermore, the intra-articular administration of the alkylmodified HA as a treatment for OA, thanks to its site-selectivity and solubility, can overcome the common issues of the small molecule MMP inhibitors, such as systemic distribution and toxicity. 871 EVALUATION OF A POLYACRYLAMIDE HYDROGEL IN THE TREATMENT OF INDUCED OSTEOARTHRITIS IN A GOAT MODEL: A RANDOMIZED CONTROLLED PILOT STUDY A. Tnibar y, A-B. Persson y, H. Nielsen z, E. Svalastoga x, U. Westrup x, F. McEvoy x, J. Knudsen k, P.D. Thomsen x, L.C. Berg x, S. Jacobsen y, L.H. Christensen {. yDept. of Large Animal Sci.Univ. of Copenhagen, Taastrup, Denmark; zDept. of Vet. Disease Biology Univ. of Copenhagen, Copenhagen, Denmark; xDept. for Clinical Vet. & Animal Sci. Univ. of Copenhagen, Copenhagen, Denmark; kDairy TechnologyUniv. of Copenhagen, Copenhagen, Denmark; {RigsHosp.et Univ. of Copenhagen, Copenhagen, Denmark Purpose: Polyacrylamide hydrogel (PAAG) is an inert, non-degradable, non-immunogenic polymer gel with high viscoelasticity consisting of 97.5% sterile water and 2.5% cross-linked polyacrylamide. Its biocompatibility in soft tissues has been demonstrated. PAAG has recently been tested for the treatment of osteoarthritis (OA) in horses with highly encouraging results; however no standardized experimental studies have been done to explore its efficacy. The purpose of this study was to evaluate PAAG in the treatment of induced OA in a goat model. Methods: A randomized controlled study was conducted involving goats with induced OA on the left stifle (knee) joint. OA was surgically induced by the transection of the medial collateral ligament, the bisection of the medial meniscus at its midpoint and partial-thickness incisions of the cartilage of the medial tibial plateau. Goats were allowed free exercise, and 3 months after surgery they were randomly divided into 2 groups: group 1 (n1⁄4 4): PAAG and group 2 (n1⁄4 2): saline solution (control). Treatments were injected intraarticularly. MRI of the left knee had been performed prior to surgery, at the time of injection (3 months) and 4, 5 and 7 months post-surgery. T1, T2/PD and Stir weighted MRI images were used to assess OA. All goats were clinically evaluated on ground and on treadmill and videotaped for evaluation by 3 blinded observers. Haematology, biochemistry and acute phase proteins were also assessed. The goats were euthanized 7 months after surgery, and gross pathology and histopathology, including immunohistochemistry for nerve endings (n 1⁄4 3 joints), were performed on both femorotibial joints. The hardness of the joint capsule was measured in both groups using Instron 5564 testing system (HIS GlobalSpec, MA, USA). Results: At the end of the study, 75 % of the goats treated with PAAG were clinically sound, and 25 % of them had not improved, whereas the 2 control goats were still lame. In both groups, the values of haematology, biochemistry, or acute phase proteins werewithin normal range. MRI showed that in group one, 3 out of 4 goats had a decrease followed by a stabilization of OA lesions, while 1 goat had a mild progression of the OA lesions. In group 2, both goats had a mild or marked increase of OA lesions. Gross pathology inspection in group 1 demonstrated that all the operated knees showed typical signs of OA. The inner synovial lining was thickened, and the cartilage surface was uneven in all cases. The gel was seen in various amounts adhering to the inner side of the joint capsule in all the goats of group 1. Gross inspection of both goats in group 2 also showed cartilage lesions and synovial thickening, but the histopathological investigations revealed this to be more prominent in group 1 than in group 2. It comprised angiogenesis, collagen and synovial cell increase, and in the injected goats, also the gel. The nerve endings were normal looking and in normal numbers. The investigation of the joint capsule hardness showed that in the treated knee of the goats of group 1, the medial side (injected with PAAG) was always less hard than the lateral side. Conclusions: This study demonstrated the efficacy of a novel treatment of OA, with 75 % of the goats treated with PAAG being clinically sound. Treatment with PAAG did not have any influence on haematology, biochemistry, or acute phase proteins. It induced a moderate synovial hyperplasia of the inner side of the capsule with trapped (integrated) gel, increased angiogenesis and collagen production. Preliminary pathology and joint capsule hardness data suggest that PAAG might act mainly on the joint soft tissue and especially the synovial membrane. PAAG might have 2 effects on OA joints: 1Joint capsule was less hard on the treated (medial) than on the non-treated (lateral) side and had a lower hardness when compared to group 2. OA joints typically show joint stiffness a major source of pain in OA. By decreasing the joint capsule hardness, and thus joint stiffness, PAAG might relieve the pain in the OA joint (“disease-modifying” effect). 2MRI and pathology investigations have revealed a stabilization of OA lesions in the goats of group 1, which might be explained by the mechanical effect through the high viscosupplementation provided by PAAG that was still present in the joint cavity (“disease-stabilizing” effect). No adverse reaction was seen following intraarticular injection of PAAG. More investigations are needed to fully understand the mechanism of action of PAAG in improving clinical signs and in stabilizing OA. This pilot study may be used as a basis for further studies using larger animal numbers. 872 EVALUATION OF NANOSTRUCTURED VECTORS FOR THE TREATMENT OF OSTEOARTICULAR PATHOLOGIES M. Riffault y, J. Scala-Bertola y, J-B. Vincourt y, J-L. Six z, P. Netter y, P. Gillet y, J. Verges x, L. Grossin y. yUMR7365 CNRS, Vandoeuvre les nancy, France; zUMR7568 CNRS, Nancy, France; xBioIberica, Barcelona, Spain Purpose: One of the major problems in treatment of osteoarticular diseases is to reach cells inside the matrix to provide drug. Indeed, cartilage is an avascular tissue with a few cells feed by diffusion through a dense protein network (collagens, glycosaminoglycans). In this work we have designed polymeric nanoparticles (NPs) of poly (D, L-lactic/ glycolic acid)(PLGA) synthesized by a double emulsion method, which are biocompatible, biodegradable and can encapsulate water-soluble agents. Our NPs are labelled with BSA coupled to a fluorescent dye (Cyanine-3) to follow them by epifluorescent microscopy. As articular Initial + 16ml XOD +32 mL XOD HA 0.8% MW 787 000 Da 621 450 Da 498 900 Da Mannitol 3.5% + HA 0.8% MW 768 900 Da 717 750 Da 677 150 Da